Drug Profile
NG 350A
Alternative Names: NG-350ALatest Information Update: 09 Jan 2023
Price :
$50
*
At a glance
- Originator PsiOxus Therapeutics
- Developer Akamis Bio; Cancer Research Institute; Parker Institute for Cancer Immunotherapy
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD40 antigen stimulants; Gene transference; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Adenocarcinoma; Carcinoma
Most Recent Events
- 09 Jan 2023 Akamis Bio anticipates the initiation of a set of expansion cohort proof-of-concept studies for NG 350A in epithelial-derived Solid tumor in early 2024
- 05 Jan 2023 PsiOxus Therapeutics is now called Akamis Bio
- 03 Jun 2022 Pharmacodynamics, efficacy and adverse events data from the phase I FORTITUDE trial in Solid tumours presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)